Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Current Opinion in Drug Discovery & Development|January 5, 2010
The biological effects of isoform-specific PI3-kinase inhibitionNathan T Ihle, Garth PowisMolecular Cell|March 18, 2017
The Pten-Parkin Axis: At the Nexus of Cancer and NeurodegenerationNathan T Ihle, Robert T AbrahamPhysical Review. E, Statistical, Nonlinear, and Soft Matter Physics|February 3, 2004
Budding of crystalline domains in fluid membranesT Kohyama, D M Kroll, G GompperCurrent Cancer Drug Targets|December 17, 2010
PI-3-Kinase inhibitors in colorectal cancerN T Ihle, G Powis, S KopetzBMC Genomics|June 15, 2016
Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicineZhou Zhu, Nathan T Ihle, Paul A Rejto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Stability of phosphoprotein as a biological marker of tumor signalingAmanda F Baker, Tomislav Dragovich, Nathan T Ihle, et al.Cancer Chemotherapy and Pharmacology|February 18, 2006
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signalingRyan Williams, Amanda F Baker, Nathan T Ihle, et al.Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|October 11, 2005
Enhanced dispersion in cylindrical packed bedsR S Maier, D M Kroll, R S Bernard, et al.Molecular Cancer Therapeutics|January 14, 2009
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activityNathan T Ihle, Robert Lemos, David Schwartz, et al.Cancer Research|January 2, 2009
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistanceNathan T Ihle, Robert Lemos, Peter Wipf, et al.Pageof 3